ENVB · Registration Statement (Form S-1) · Filed February 10, 2026

Enveric Biosciences Inc — S-1 exhibit

ex107.htm

Enveric Biosciences Inc on Boardroom Alpha

Exhibit 107

Calculation of Filing Fee Tables

Form S-1

(Form Type)

Enveric Biosciences, Inc.

(Exact Name of Each Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

Security Type	Security Class Title	Fee Calculation or Carry Forward Rule	Amount Registered ⁽¹⁾		Proposed Maximum Offering Price Per Unit			Maximum Aggregate Offering Price		Fee Rate		Amount of Registration Fee
Equity	Common Stock, par value $0.01 per share ("Common Stock"),underlying warrants to purchase Common Stock	Other		680,620		$2.70	⁽²⁾	$	1,837,674.00		0.00013810	$	253.78
Total Offering Amounts								$	1,837,674.00			$	253.78
Total Fees Previously Paid													-
Total Fee Offsets													-
Net Fee Due												$	253.78

(1)	Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), the number of shares registered hereunder includes such additional number of shares of common stock, par value $0.01 per share (the “Common Stock”) of Enveric Biosciences, Inc. (the “Company”), as are required to prevent dilution resulting from a stock split, stock dividend or similar transaction.

(2)	The offering price has been estimated solely for the purposes of the calculation of the registration fee. The offering price has been calculated in accordance with the manner described in paragraphs (c) and (h) of Rule 457 under the Securities Act and is based upon the average of high and low prices reported by the Nasdaq Capital Market on February 5, 2026, a date within five (5) business days prior to the date of the filing of this Registration Statement.

N/A

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer